It is currently Sun Mar 29, 2015 12:58 pm

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Opinions on NDC-1308?

This is exciting stuff I've read. Any opinions on this drug?
Read more : Opinions on NDC-1308? | Views : 220 | Replies : 0


Alkermes reports positive data on multiple sclerosis drug

Alkermes reports positive data on multiple sclerosis drug ALKS 8700

Alkermes plc has reported positive top-line data from a phase I study on its experimental MS drug, ALKS 8700. ALKS 8700 is a novel monomethyl fumarate (MMF) molecule being developed for the treatment of MS..... Read More - http://www.ms-uk.org/emergingtherapies
Read more : Alkermes reports positive data on multiple sclerosis drug | Views : 362 | Replies : 0




Could anatabine citrate be a used as a MS therapy?

Drug development company Rock Creek Pharmaceuticals has announced a new clinical trial application with the Medicines Healthcare Products Regulatory Agency (MHRA) has been approved. The company is set to proceed with a Phase I study of Anatabine Citrate, a chemical that is found naturally in aubergine, potatoes, green tomatoes and other members of the Solanaceae family of plants, as well as in tobacco and tobacco smoke. The chemical is known for its anti-inflammatory properties unique ...
Read more : Could anatabine citrate be a used as a MS therapy? | Views : 556 | Replies : 1


Phase I trial data for remyelinating antibody in MS released

Acorda Therapeutics has today announced safety and tolerability data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis. The trial, which followed participants for up to six months after receiving a single dose of rHIgM22, found no dose-limiting toxicities at any of the five dose levels studied. Based on this, the Company intends to advance clinical development of rHIgM22..... Read More - http://www.ms-uk.org/emergingtherapies
Read more : Phase I trial data for remyelinating antibody in MS released | Views : 516 | Replies : 1


Primary & secondary progressive MS drug progress update

MedDay, a biotechnology company that develops new drugs for nervous system disorders, announced an update on the progress of its development pipeline with its lead product MD1003 for the treatment of primary and secondary progressive multiple sclerosis (MS). The first study is expected to be complete in early 2015, while the second should be complete in late 2015....... Read More - http://www.ms-uk.org/emergingtherapies
Read more : Primary & secondary progressive MS drug progress update | Views : 518 | Replies : 0


Results from phase1b APD334 for autoimmune diseases released

Arena Pharmaceuticals, Inc. released the first results from its phase 1b trial that for the evaluation of an oral drug candidate called APD334 for the treatment of autoimmune diseases, such as multiple sclerosis (MS). The multiple ascending dose clinical trial demonstrated encouraging findings about the drug, which is designed to target the sphingosine 1-phosphate subtype 1 (S1P1) receptor............ Read More - http://www.ms-uk.org/emergingtherapies
Read more : Results from phase1b APD334 for autoimmune diseases released | Views : 357 | Replies : 0


Update on progress of progressive MS drug MD1003

MedDay provides update on progress of progressive MS drug MD1003

MedDay has provided an update on the progress of its lead product MD1003 for the treatment of primary and secondary progressive multiple sclerosis (MS), which is expected to complete its first pivotal study in Q1 2015. A second pivotal study is on track for completion by the end of 2015.... Read More - http://www.ms-uk.org/emergingtherapies
Read more : Update on progress of progressive MS drug MD1003 | Views : 968 | Replies : 6




New MS drug shows some promise in repairing eye nerve damage

Possible new MS drug shows some promise in repairing eye nerve damage

Biogen Idec Inc’s experimental drug for multiple sclerosis showed signs that it could help repair nerve damage in patients’ eyes, a tentatively positive step for a drug aimed at reversing progression of the disease.

In a mid-stage trial of 82 patients, Biogen’s drug showed a 34 percent improvement in those who completed the study. The result fell a hair below the threshold for ...
Read more : New MS drug shows some promise in repairing eye nerve damage | Views : 424 | Replies : 0


 

Login  •  Register


Statistics

Total posts 224393 • Total topics 23431 • Total members 14842


Contact us | Terms of Service